Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GD2-targeted CAR-T for Relapsed or Refractory Neuroblastoma
NCT02919046Phase 2Unknown
- Sponsor
- Sinobioway Group Co., Ltd.
- Start
- Sep 2016
- Primary completion
- Sep 2020
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in neuroblastoma, sponsored by Sinobioway Group Co., Ltd. Primary endpoint: Overall Efficiency at 90 days. Status: unknown.
02
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT02919046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02919046.